NYSE - Delayed Quote • USD
Compare
At close: June 20 at 4:00 PM EDT
After hours: June 20 at 7:59 PM EDT
Line
Candle
Baseline
Mountain
Bar
Loading Chart for ABBV
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
171.36 - Open
171.18 - Bid --
- Ask --
- Day's Range
170.02 - 172.81 - 52 Week Range
130.96 - 182.89 - Volume
5,811,058 - Avg. Volume
5,160,527 - Market Cap (intraday)
303.959B - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
51.23 - EPS (TTM)
3.36 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield 6.20 (3.60%)
- Ex-Dividend Date Apr 12, 2024
- 1y Target Est
184.08
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
50,000
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - General
Industry
More about AbbVie Inc.
Recent News: ABBV
All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: ABBV
Trailing total returns as of 6/20/2024, which may include dividends or other distributions. Benchmark is
YTD Return
ABBV
13.18%
S&P 500
14.75%
1-Year Return
ABBV
29.20%
S&P 500
24.12%
3-Year Return
ABBV
71.53%
S&P 500
31.36%
5-Year Return
ABBV
178.30%
S&P 500
87.02%
Compare To: ABBV
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
172.13
+0.45%
Mkt Cap 303.959B
Industry Drug Manufacturers—General
147.78
+1.46%
Mkt Cap 355.659B
Industry Drug Manufacturers—General
129.67
+1.31%
Mkt Cap 328.429B
Industry Drug Manufacturers—General
27.74
+1.20%
Mkt Cap 157.191B
Industry Drug Manufacturers—General
41.04
+0.56%
Mkt Cap 83.192B
Industry Drug Manufacturers—General
309.89
+1.27%
Mkt Cap 166.236B
Industry Drug Manufacturers—General
885.99
-0.61%
Mkt Cap 842.049B
Industry Drug Manufacturers—General
68.49
+8.46%
Mkt Cap 85.328B
Industry Drug Manufacturers—General
78.56
+0.18%
Mkt Cap 243.576B
Industry Drug Manufacturers—General
105.74
+0.76%
Mkt Cap 217.604B
Industry Drug Manufacturers—General
40.76
-0.46%
Mkt Cap 83.765B
Industry Drug Manufacturers—General
Statistics: ABBV
Valuation Measures
As of 6/20/2024
Market Cap
303.96B
Enterprise Value
359.89B
Trailing P/E
51.23
Forward P/E
15.34
PEG Ratio (5yr expected)
0.45
Price/Sales (ttm)
5.61
Price/Book (mrq)
37.96
Enterprise Value/Revenue
6.62
Enterprise Value/EBITDA
19.45
Financial Highlights
Profitability and Income Statement
Profit Margin
11.02%
Return on Assets (ttm)
7.71%
Return on Equity (ttm)
56.24%
Revenue (ttm)
54.4B
Net Income Avi to Common (ttm)
5.95B
Diluted EPS (ttm)
3.36
Balance Sheet and Cash Flow
Total Cash (mrq)
18.07B
Total Debt/Equity (mrq)
924.06%
Levered Free Cash Flow (ttm)
23.61B
Research Analysis: ABBV
Company Insights: ABBV
Research Reports: ABBV
People Also Watch
ABT Abbott Laboratories
106.57
+2.48%
BMY Bristol-Myers Squibb Company
41.04
+0.56%
JNJ Johnson & Johnson
147.78
+1.46%
GILD Gilead Sciences, Inc.
68.49
+8.46%
MRK Merck & Co., Inc.
129.67
+1.31%
MMM 3M Company
101.66
+0.88%
CVX Chevron Corporation
156.64
+2.16%
LLY Eli Lilly and Company
885.99
-0.61%
CVS CVS Health Corporation
61.00
-0.02%
PEP PepsiCo, Inc.
166.68
+0.12%
AMGN Amgen Inc.
309.89
+1.27%
O Realty Income Corporation
53.01
-0.17%
PFE Pfizer Inc.
27.74
+1.20%
WBA Walgreens Boots Alliance, Inc.
15.87
-1.49%
AVGO Broadcom Inc.
1,734.56
-3.77%
UNH UnitedHealth Group Incorporated
484.52
+0.72%